Sensus Healthcare Q2 revenue $4.5M (-63% YoY), net loss $0.4M vs $3.5M profit last year

Sensus Healthcare, Inc.

2023-Q2 EPS reported -$0.14 revenue$7,941,000

Revenue $4.5M, down 63% YoY from $12.1M; net loss $0.4M ($0.02/sh) vs net income $3.5M ($0.21/sh) in Q2 2022.
Shipped 13 SRT systems (down from 33 YoY) but up from 10 in Q1; total installed base 708 systems worldwide.
Cash $20.1M, no debt; gross margin 57.9% vs 68.3% a year ago on lower volume and higher vendor costs.
Guidance: expects to ship at least 60 SRT systems in 2023 and return to profitability in H2 2023.
New UK/Ireland distribution with MIS Healthcare; first sale in Ireland; international expansion progressing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.92

Sensus Healthcare, Inc. reported the three and six months ended June 30, 2023 results: revenue $4.5 million, net income $0.4 million, or $0.02 per share (net loss), EPS $0.02 per share. Guidance reaffirmed.

Period: the three and six months ended June 30, 2023
Revenue: $4.5 million
Net income: $0.4 million, or $0.02 per share (net loss)
EPS: $0.02 per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

financial results for the three and six months ended June 30, 2023. Highlights from the second quarter of 2023 and recent weeks include the following: ● Achieved revenues of $4.5 million, an increase of 33% from $3.4 million for the first quarter of 2023 and a decrease from $12.1 million in the prior-year quarter reflecting lower SRT unit sales ● Shipped 13 SRT

View on SEC.gov

Browse all earnings releases →

Sensus Healthcare, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-062982

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.